Equities
Health CareHealth Care Equipment & Services
  • Price (NOK)33.38
  • Today's Change1.02 / 3.15%
  • Shares traded69.98k
  • 1 Year change-46.75%
  • Beta1.0218
Data delayed at least 15 minutes, as of Aug 19 2019 15:25 BST.
More ▼

Profile data is unavailable for this security.

About the company

Nordic Nanovector ASA is a Norway-based company active in the biotechnology industry. It is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product candidate is Betalutin, comprising a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide (Lutetium 177). It is designed improve treatment of Non-Hodgkin Lymphoma (NHL) and advanced through clinical development. Additionally, the Company is engaged in the development of its Antibody-Radionuclide-Conjugate (ARC) portfolio to treat various selected cancer indications. It has two subsidiaries, Nordic Nanovector GmbH and Nordic Nanovector Ltd.

  • Revenue in NOK (TTM)0.00
  • Net income in NOK-338.63m
  • Incorporated2009
  • Employees45.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cantargia AB0.00-94.22m1.04bn9.00--4.40-----1.53-1.530.003.470.00----0.00-39.76-49.51-43.69-57.92------------0.00-------51.30------
Oasmia Pharmaceutical AB1.85m-159.56m1.05bn57.00--2.66--569.63-0.8879-0.88790.01031.890.0033-0.3360.6531---28.16-26.46-42.65-41.25292.53386.54-8,637.17-5,146.080.7304-6.650.2476---37.52101.23-44.92---19.54--
Moberg Pharma AB (publ)18.76m-15.92m1.09bn19.00--1.0736.4758.09-0.980232.971.1559.880.0134.140.4286543,432.40-1.111.35-1.491.461,044.68---84.854.262.19-87.290.3744---98.96-50.77-349.54------
Photocure ASA199.47m-26.81m1.14bn71.00--6.81--5.69-1.24-1.249.187.660.86650.91210.252,809,394.00-11.65-7.27-14.41-8.3590.4892.74-13.44-13.112.76--0.0489--20.2816.77-5.80--7.13--
Immunicum AB0.00-91.65m1.14bn11.00--3.26-----1.72-1.720.004.090.00----0.00-34.17---36.42-------------6,547.730.00-------21.81------
Q linea AB1.43m-139.02m1.32bn61.00--3.25--926.98-7.81-7.810.078818.790.0054272.3371.1228,849.06-52.20---58.19---1,369.39---9,745.13--11.62-74,501.000.0021---28.93---89.09------
Hofseth Biocare ASA60.84m-83.25m1.35bn28.00--20.06--22.24-0.3054-0.30540.22250.22880.30661.886.41---41.96-43.71-75.19-77.7813.0121.43-136.85-187.250.6764-152.220.6531---8.29-0.7078-414.53---19.64--
IRLAB Therapeutics AB16.79k-70.88m1.45bn26.00--7.92--86,116.88-1.93-1.930.00054.840.0001--0.004720.00-41.94---44.95-------422,055.60-----274.250.0285---83.49---31.79------
Bonesupport Holding AB100.30m-178.62m1.62bn78.00--9.01--16.16-3.72-3.722.093.720.31330.57815.111,493,083.00-55.79---65.92--85.37---178.08--3.31-3,171.150.0581---25.27---36.89------
Surgical Science Sweden AB63.38m-4.73m1.64bn38.00--17.20319.5725.94-1.04-1.0413.9715.240.6873-0.17458.941,835,865.00-5.13---6.30--101.74---7.47--2.46-1,545.670.00--14.58---75.43------
Orphazyme A/S-134.05bn-134.05bn1.69bn57.00-----------------------------------------------------81.93------
Nordic Nanovector ASA0.00-338.63m1.78bn45.00--3.65-----6.75-6.750.008.860.00----0.00-54.52-34.38-62.03-38.09-------73,984.18----0.0125---100.00---14.96--48.77--
Calliditas Therapeutics AB0.00-127.23m1.91bn13.00--3.22-----6.64-6.640.0016.440.00----0.00-40.82---44.93--------------0.00-------52.14------
Orexo AB764.32m170.18m1.92bn130.0011.503.729.742.515.155.1523.1715.930.62690.8262.736,350,388.0013.96-1.4422.67-2.1082.6277.8022.27-2.281.91--0.4099--21.6612.77494.40---43.66--
Infant Bacterial Therapeutics AB0.00-30.00m2.37bn8.00--4.72-----2.86-2.860.0049.530.00----0.00-5.55-17.29-5.61-18.00-------28,727.13---32.950.00---100.00---12.31------
Data as of Aug 19 2019. Currency figures normalised to Nordic Nanovector ASA's reporting currency: Norwegian Krone NOK

Institutional shareholders

14.64%Per cent of shares held by top holders
HolderShares% Held
Folketrygdfondetas of 18 Jun 20193.51m6.37%
Nordea Investment Management AB (Norway)as of 28 Jun 20191.52m2.76%
KLP Kapitalforvaltning ASas of 31 Jul 2019821.51k1.49%
Sissener ASas of 18 Jun 2019500.00k0.91%
Dimensional Fund Advisors LPas of 31 May 2019413.91k0.75%
BlackRock Fund Advisorsas of 08 Aug 2019326.45k0.59%
Max Mitteregger Kapitalf�rvaltning ABas of 31 Dec 2016300.00k0.54%
Storebrand Asset Management ASas of 31 Jul 2019284.49k0.52%
DNB Asset Management ASas of 28 Jun 2019198.76k0.36%
TIAA-CREF Investment Management LLCas of 30 Jun 2019191.82k0.35%
More ▼
Data from 31 Dec 2016 - 31 Jul 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.